ljc 10627 has been researched along with Hematologic Malignancies in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, L; Liu, M; Rao, Q; Wang, S; Yang, Y; Zhang, J; Zhu, H | 1 |
| Isobe, Y; Kanemitsu, N; Masuda, A; Sugimoto, K; Tsukune, Y; Yahata, Y | 1 |
| Akiyama, N; Ando, K; Aoki, S; Arai, A; Chou, T; Dan, K; Fujisawa, S; Hatake, K; Higashihara, M; Hirose, T; Ishida, Y; Kida, M; Kouzai, Y; Miyazaki, K; Nakagawa, Y; Ohyashiki, K; Okamoto, S; Suzuki, K; Taniguchi, S; Tomoyasu, S; Urabe, A; Usuki, K | 1 |
1 trial(s) available for ljc 10627 and Hematologic Malignancies
| Article | Year |
|---|---|
Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Female; Fever; Hematologic Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Thienamycins; Treatment Outcome | 2011 |
2 other study(ies) available for ljc 10627 and Hematologic Malignancies
| Article | Year |
|---|---|
Optimal dosing regimen of biapenem based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies.
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Febrile Neutropenia; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Prospective Studies | 2023 |
Clinical and microbiological effects of biapenem in febrile neutropenic patients with hematologic malignancies.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Fever; Hematologic Neoplasms; Humans; Neutropenia; Thienamycins | 2009 |